These findings together indicate that CLDN22 is linked to both shared and distinct BPs in LGG and GBM, potentially driving subtype‐specific mechanisms of glioma growth and therapeutic response (Supporting Information 4: Table S2). Here, CLDN22 is linked to glioblastoma.